Let's look beyond this piece of bad news from regulators.Vaccine maker Novavax (NVAX -1.64%) has had a rollercoaster of a year. In May, the company's shares soared after it announced a lucrative agreement with biotech giant Sanofi. It's been mostly downhill for Novavax since then, though that's likely due to some profit taking by investors.However, Novavax's shares recently dropped by about 20% in one day after it announced a clinical setback. The biotech's stock price is still up by more than 100% for the ...

Key Takeaways The Food and Drug Administration put clinical holds on Novavax's COVID-19 and flu combination vaccine and its standalone flu shot because of safety concerns. The moves came as one patient who took the combination shot reported nerve damage. The company said it was working with the FDA to get the information necessary to resolve the issue and allow the company to move forward with testing. Novavax (NVAX) shares plummeted nearly 20% Wednesday after the Food and Drug Administration (FDA) stopped ...

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Novavax on Wednesday said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and influenza and a standalone flu vaccine, sending the company's shares down sharply. The biotech company's stock fell nearly 20% on Wednesday. The so-called clinical hold is due to a single rep ...

Core Viewpoint - Novavax's stock performance shows a positive shift, with upcoming earnings expected to reveal significant year-over-year growth despite a decline in revenue [1][3][4]. Company Performance - Novavax's stock closed at $12.91, reflecting a gain of 1.77% in the latest trading session, outperforming the S&P 500, which fell by 0.21% [1]. - Over the past month, Novavax shares increased by 3.17%, while the Medical sector experienced a loss of 3.28% and the S&P 500 gained 5.94% [2]. Earnings Projections - For the upcoming earnings report, Novavax is projected to report earnings of -$0.89 per share, indicating a year-over-year growth of 29.37% [3]. - The Zacks Consensus Estimate for revenue is $52.32 million, which represents a significant decline of 72.02% compared to the previous year [3]. - For the entire fiscal year, earnings are expected to be -$0.97 per share, with revenue projected at $751.97 million, reflecting changes of +82.07% and -23.56% respectively from the prior year [4]. Analyst Estimates - Recent adjustments to analyst estimates for Novavax are crucial as they indicate changing business trends, with positive revisions suggesting a favorable outlook on the company's health and profitability [5]. - The Zacks Rank system, which incorporates these estimate changes, currently ranks Novavax at 3 (Hold), with a recent upward shift of 6.28% in the EPS estimate [7]. Industry Context - Novavax operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 84, placing it in the top 34% of over 250 industries [7].

Shares of Novavax (NVAX, Financial), a biotechnology firm specializing in vaccine development, experienced a significant drop of 5.11%. The stock is currently priced at $12.92 with a trading volume of approximately 3.03 million shares, reflecting a turnover rate of 1.89% and a price fluctuation of 6.10%. Recent financial data reveals Novavax achieved a revenue of $415 million, net earnings of $162 million, and earnings per share of $1.09. The company's gross profit stands at $379 million, with a price-to-ea ...

Ruxandra Draghia-Akli, MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organization Dr. Draghia-Akli will be integral in strategically evaluating the Company's pipeline and opportunities for its Matrix-M™ adjuvant and protein-based technology platform GAITHERSBURG, Md., Sept. 25, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvan ...

The latest trading session saw Novavax (NVAX) ending at $12.80, denoting a -0.85% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.28%. Meanwhile, the Dow experienced a rise of 0.15%, and the technology-dominated Nasdaq saw an increase of 0.15%. Coming into today, shares of the vaccine maker had gained 7.67% in the past month. In that same time, the Medical sector gained 0.38%, while the S&P 500 gained 2%. The upcoming earnings release of Novavax will b ...

Core Points - Novavax's updated COVID-19 vaccine (2024-2025 Formula) is now available at thousands of locations across the U.S. for individuals aged 12 and older [1][3] - The vaccine is the only protein-based option available this fall and has received Emergency Use Authorization (EUA) from the FDA on August 30, 2024 [3][5] - The vaccine targets the JN.1 variant and has shown cross-reactivity against other lineage viruses [4][12] Availability and Distribution - The updated vaccine is expected to be widely available through agreements with major pharmacy retailers including CVS, Walgreens, and Costco, among others [3][4] - The number of locations stocking the vaccine has more than doubled compared to the previous year, enhancing consumer access [4] Vaccine Composition and Technology - The Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2705) is formulated to target the JN.1 variant and utilizes Novavax's Matrix-M adjuvant to enhance the immune response [12][13] - The vaccine is presented in a pre-filled syringe for convenience and is stored at 2° to 8°C, allowing for the use of existing vaccine supply chains [4][12] Safety and Efficacy - The vaccine is indicated for active immunization against COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older [7] - Contraindications include a known history of severe allergic reactions to any component of the vaccine [8] - Adverse reactions may include injection site pain, fatigue, and muscle pain, among others [11]

Novavax, Inc. (NASDAQ:NVAX) Baird 2024 Global Healthcare Conference September 10, 2024 3:10 PM ET Unidentified Company Representative I'd like to thank you all for joining us for Novavax Corporate presentation certainly for Baird for having us here again this year. This is always such a great forum and it coincides with the beginning of the vaccination season for COVID vaccines. We're going to talk a lot about our technology today, but really important announcement just very recently with the authorization ...

Regulators recently approved an updated COVID shot from Novavax. Struggling biotech Novavax (NVAX -0.72%) was a hot buy a few years ago as it was in the midst of developing a vaccine for COVID-19. Ultimately, it did produce an approved vaccine, but it was a bit late and did not end up generating nearly as much in revenue as it could have if it had obtained approval much earlier. And since 2022, a sell-off has ensued, with the stock losing more than 91% of its value. Recently, there's been some renewed excit ...